During his 30 years of experience in public markets & advising Global Institutional clients across Equity, Debt and Structured products, Clifford has worked in NYC, London and Johannesburg; Clifford’s experience lies mostly in Global Investment Banks (14 years with BAML) and the past 8 years with EY, where he has led the M&A and Capital Markets practice.
Sarah is the Chief Business Officer and brings over 20 years of immunological expertise focusing on developing immuno-therapeutics across areas of Immune-Oncology, Autoimmunity, Inflammation and Infection. She has worked both as an academic and commercial immunologist recently leading UK and European teams that offer complex preclinical business development service. Sarah has a global reach and perspective across the industry; with a wealth of preclinical and clinical expertise she helps clients navigate their drug discovery programs with speed and agility. Her previous positions include Sr Client Manager at Charles River Laboratories, Business Development KWS Biotest, Research Fellowship position at the University of Bristol.
Rhiannon is the Chief Scientific officer of Nexus BioQuest and brings over 20 years’ experience working in the field of immunology across CRO and academic sectors. Her previous positions include Director of Science at Charles River Laboratories, Principal Scientist at KWS Biotest, a Wellcome Trust Career Re-entry Fellowship and a Postdoctoral fellowship at NCI, NIH. Rhiannon has a track record of strong scientific leadership; working closely with her team to identify to design custom assays, identify areas for growth and new technologies. She has a diverse background in autoimmunity, inflammation and immune-oncology and has worked with clients to design and implement research in these areas across all therapeutic modalities. She remains fascinated by the complexity of the immune system and how the latest findings and research in the field of immunology can be translated into assays to help advance clients drug discovery programs.